Achten Niek B, Klingenberg Claus, Benitz William E, Stocker Martin, Schlapbach Luregn J, Giannoni Eric, Bokelaar Robin, Driessen Gertjan J A, Brodin Petter, Uthaya Sabita, van Rossum Annemarie M C, Plötz Frans B
Department of Pediatrics, Tergooi Hospital, Blaricum, the Netherlands.
Faculty of Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
JAMA Pediatr. 2019 Nov 1;173(11):1032-1040. doi: 10.1001/jamapediatrics.2019.2825.
The neonatal early-onset sepsis (EOS) calculator is a clinical risk stratification tool increasingly used to guide the use of empirical antibiotics for newborns. Evidence on the effectiveness and safety of the EOS calculator is essential to inform clinicians considering implementation.
To assess the association between management of neonatal EOS guided by the neonatal EOS calculator (compared with conventional management strategies) and reduction in antibiotic therapy for newborns.
Electronic searches in MEDLINE, Embase, Web of Science, and Google Scholar were conducted from 2011 (introduction of the EOS calculator model) through January 31, 2019.
All studies with original data that compared management guided by the EOS calculator with conventional management strategies for allocating antibiotic therapy to newborns suspected to have EOS were included.
Following PRISMA-P guidelines, relevant data were extracted from full-text articles and supplements. CHARMS (Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies) and GRADE (Grades of Recommendation, Assessment, Development and Evaluation) tools were used to assess the risk of bias and quality of evidence. Meta-analysis using a random-effects model was conducted for studies with separate cohorts for EOS calculator and conventional management strategies.
The difference in percentage of newborns treated with empirical antibiotics for suspected or proven EOS between management guided by the EOS calculator and conventional management strategies. Safety-related outcomes involved missed cases of EOS, readmissions, treatment delay, morbidity, and mortality.
Thirteen relevant studies analyzing a total of 175 752 newborns were included. All studies found a substantially lower relative risk (range, 3%-60%) for empirical antibiotic therapy, favoring the EOS calculator. Meta-analysis revealed a relative risk of antibiotic use of 56% (95% CI, 53%-59%) in before-after studies including newborns regardless of exposure to chorioamnionitis. Evidence on safety was limited, but proportions of missed cases of EOS were comparable between management guided by the EOS calculator (5 of 18 [28%]) and conventional management strategies (8 of 28 [29%]) (pooled odds ratio, 0.96; 95% CI, 0.26-3.52; P = .95).
Use of the neonatal EOS calculator is associated with a substantial reduction in the use of empirical antibiotics for suspected EOS. Available evidence regarding safety of the use of the EOS calculator is limited, but shows no indication of inferiority compared with conventional management strategies.
新生儿早发型败血症(EOS)计算器是一种临床风险分层工具,越来越多地用于指导新生儿经验性抗生素的使用。EOS计算器有效性和安全性的证据对于告知考虑实施该工具的临床医生至关重要。
评估由新生儿EOS计算器指导的新生儿EOS管理(与传统管理策略相比)与减少新生儿抗生素治疗之间的关联。
从2011年(EOS计算器模型推出)至2019年1月31日,在MEDLINE、Embase、科学网和谷歌学术进行了电子检索。
纳入所有具有原始数据的研究,这些研究比较了由EOS计算器指导的管理与传统管理策略在为疑似患有EOS的新生儿分配抗生素治疗方面的情况。
按照PRISMA-P指南,从全文文章和补充材料中提取相关数据。使用CHARMS(预测建模研究系统评价的关键评估和数据提取清单)和GRADE(推荐分级、评估、制定和评价)工具评估偏倚风险和证据质量。对EOS计算器和传统管理策略有单独队列的研究进行随机效应模型的荟萃分析。
在由EOS计算器指导的管理与传统管理策略之间,因疑似或确诊EOS接受经验性抗生素治疗的新生儿百分比差异。与安全相关的结局包括EOS漏诊病例、再次入院、治疗延迟、发病率和死亡率。
纳入了13项相关研究,共分析了175752名新生儿。所有研究均发现经验性抗生素治疗的相对风险显著降低(范围为3%-60%),支持EOS计算器。荟萃分析显示,在包括无论是否暴露于绒毛膜羊膜炎的新生儿的前后对照研究中,抗生素使用的相对风险为56%(95%CI,53%-59%)。关于安全性的证据有限,但EOS计算器指导的管理(18例中的5例[28%])与传统管理策略(28例中的8例[29%])漏诊EOS病例的比例相当(合并比值比,0.96;95%CI,0.26-3.52;P = 0.95)。
使用新生儿EOS计算器与疑似EOS的经验性抗生素使用大幅减少相关。关于使用EOS计算器安全性的现有证据有限,但与传统管理策略相比未显示出劣势迹象。